Advanced research and development and delivery of adult and pediatric midazolam autoinjectors that have received emergency use authorization (EUA) or FDA approval for the treatment of status…

Active Definitive Contract Awarded Last action

Contract number
75A50122C00031
Awardee
Awarding agency
Obligated
$108,841,769

Award facts

Opportunity
Contract value 64% obligated
  • $108,841,769.00 Current, with exercised options
  • $170,934,645.00 Potential, with all options
Completion date 54% complete
Current and potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
France

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00004 · Provide supplemental funding, extend the period of performance for CLIN0001 and update section j list of attachments attachment 1 statement of work $4,688,783
Funding Only Action P00003 · Supplemental funding for clin 001 and revised the statement of work. $11,291,005
Other Administrative Action P00002 $0
Other Administrative Action P00001 $0
Original award $92,861,981

About this award

Written by GovTribe AI ·

The Office of the Assistant Secretary for Preparedness and Response awarded a $170.9 million definitive contract to Crossject SA on June 22, 2022, for advanced research and development and delivery of adult and pediatric midazolam autoinjectors with Emergency Use Authorization or FDA approval for treatment of status epilepticus seizures.

Place of performance is France. The contract is cost-plus-fixed-fee and extends through June 21, 2030. The originating pre-solicitation, posted June 1, 2020, sought capability statements for development and manufacture of midazolam autoinjectors to replace diazepam autoinjectors in the Strategic National Stockpile and CHEMPACK program, with requirement for FDA approval or phase 3 development status, 99.999% reliability standards, and capacity to treat both adult and pediatric populations. The current contract provides supplemental funding and extends the period of performance for the initial line item, with updates to the statement of work.

Description

As the agency reported it.

Advanced research and development and delivery of adult and pediatric midazolam autoinjectors that have received emergency use authorization (EUA) or FDA approval for the treatment of status epilepticus seizures in adult and pediatric populations (2+

Quick answers

Who was awarded contract 75A50122C00031?

75A50122C00031 was awarded to Crossject SA by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on June 22, 2022.

How much is contract 75A50122C00031 worth?

The government has obligated $108,841,769 on 75A50122C00031. Its potential value, with all options, is $170,934,645.

Was contract 75A50122C00031 competed?

The extent of competition for 75A50122C00031 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login